Adaptive Biotechnologies Corporation

The biopharmaceutical industry is nearing the one-month mark without an initial public offering in the US as biotechnology stock values continue to plummet, mirroring the slowdown across industries as

Norway's Nykode Therapeutics , which has just changed its name from Vaccibody AS , has bagged a second major pharma partner, inking a deal with Regeneron Pharmaceuticals, Inc. potentially worth up

Roche Holding AG / Genentech, Inc. global oncology partnering head Don O’Sullivan is eager to get back to the days of discussing deals in person over a glass of wine, but noted in an interview that t

Gene therapies that program the body to make therapeutic antibodies, genetic surgery that replaces anatomical surgery and cell therapies designed to attack individual cancer patients’ tumors almost so